Jeffrey A. Sonnenfeld

Elon Musk has less leverage in his battle with Donald Trump than he thinks, Yale SOM leadership expert Jeffrey Sonnenfeld and co-author Steven Tian write. But neither of the former allies can come away from this feud with a win.

Yale SOM leadership expert Jeffrey Sonnenfeld and co-author Stephen Henriques write that the CEO’s two decades as a pragmatic, stabilizing force make him an attractive alternative.

Yale SOM leadership expert Jeffrey Sonnenfeld reflects on what the next generation of leaders can learn from the late pope. ‌

Objections from business leaders played a key role in pushing the Trump Administration to reverse course on recently announced “reciprocal” tariffs, according to Yale SOM leadership expert Jeffrey Sonnenfeld and co-author Stephen Henriques. It’s a win for business, they write, but the business community remains concerned about uncertainty around economic policy.

Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian write that the administration’s unpredictable approach is bringing new corporate initiatives to a standstill and pushing the economy toward recession.

Amid warming relations with Washington, Vladimir Putin is floating new opportunities for Western companies in Russia. But Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian write that business leaders are reluctant to reengage in a dangerous setting and a faltering economy.

Yale SOM leadership expert Jeffrey Sonnenfeld writes that rather than zeroing in on waste and bureaucracy, the Department of Government Efficiency is driving out thousands of critical workers.

Yale SOM’s Jeffrey Sonnenfeld and co-authors Stephen Henriques and Steven Tian write that while there are legitimate reasons for some tariffs, the president’s arbitrary approach is worrying allies and unsettling markets.

Leadership expert Jeffrey Sonnenfeld and co-author Steven Tian look across history for examples of pitfalls that could lie ahead for Elon Musk and Donald Trump.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian.